MSSV yields 7692.31% · ABBV yields 3.06%● Live data
📍 MSSV pulled ahead of the other in Year 1
Combined, MSSV + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MSSV + ABBV for your $10,000?
Meso Numismatics, Inc. engages in the numismatic business in the United States and internationally. The company sells coins, paper currency, bullion, and medals through live auctions. It also offers banknote scanner, an application to identify key characteristics of a banknote; and sells its products through an online store, mesocoins.com. In addition, the company provides CELLGENIC FLOW EXOSOMES; CELLGENIC MSC, which excretes growth factors, cytokines, and proteins for regeneration of tissue; CELLGENIC LUMA that is derived from human umbilical cord mesenchymal stem cells, including potent growth factors, peptides, coenzymes, minerals, amino acids, vitamins, and UV radiation reducing agents for skin revitalization; VITANOVAS that offers in-home treatments to patients in need of immune modulation to help fight infections, viruses, and diseases; GCELL RESTORE, a closed-system medical device to harness the natural and restorative capabilities of adipose tissue; CELLGENIC SVF, an isolation kit system that has the ingredients and consumables for the extraction of adipose-derived stem cells from fat; CELLGENIC BONE MARROW; and CELLGENIC Platelet Rich Plasma for healing and reducing inflammation. Further, it offers training services to doctors. The company was formerly known as Pure Hospitality Solutions, Inc. and changed its name to Meso Numismatics, Inc. in September 2018. Meso Numismatics, Inc. was founded in 1999 and is based in Boca Raton, Florida.
Full MSSV Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.